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Abstract
Major contributions of the 2nd annual meeting of the International Society of Cancer Metabolism, held in Venice,
September 16–19, 2015, are here described and discussed. Among these, the impact of cancer metabolism on local
and systemic aggressiveness was analyzed in the context of interactions between cancer and stroma,
microenvironmental changes, epigenetic, and stemness modulation.
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Tumor-associated microenvironment and metabolism
have increasingly become major focuses in cancer re-
search, and discoveries in these fields will potentially
result in significant advances in treatment and diagnosis.
On September 16–19, 2015, the International Society of
Cancer Metabolism [1] organized its 2nd annual meeting
focused on “Metabolism and microenvironment in can-
cer plasticity” that covered several aspects of cancer me-
tabolism involved in local and systemic aggressiveness.
Along with 43 oral presentations and 44 poster presenta-
tions, more than 140 participants from all over the
world, including 17 invited speakers, participated in an
interdisciplinary forum to discuss recent progresses in
the field and to identify future directions that should be
explored with the highest priority. Many of the presenta-
tions focused on the interactions between tumor cells
and their surrounding microenvironment, and on how,
in turn, the tumor microenvironment, including ions
and other small molecules (e.g., CO2 and NO), released
metabolites and normal cells of the surrounding stroma
modulate cancer metabolism, behavior, and progression.
The need for new preclinical models that better repre-
sent the complexity of the cancer microenvironment
and of altered tumor metabolism, and new possible
approaches for cancer treatment and monitoring
through the study of metabolism was also discussed
(Fig. 1). The opening lecture by Paolo Sassone-Corsi
(University of California, Irvine, CA, USA) emphasized
that a multidisciplinary approach is pivotal for studying
cancer. One example is the study of the influence of the
circadian clock on cancer biology. Circadian rhythms are
governed by a molecular machinery whose function is to
maintain rhythmic precision and synchrony between
central and peripheral clocks. Most importantly, circa-
dian clocks are intrinsic time‐tracking systems with
which organisms can anticipate environmental changes
and adapt to the appropriate time of day. At the heart
of circadian regulatory pathways is the clock machin-
ery, a remarkably coordinated transcription‐translation
system that also utilizes dynamic changes in chroma-
tin transitions and epigenetic control. This epigenetic
control provides the pacemaker with a remarkable
plasticity that allows adaptation to nutritional input
and metabolic fluctuations. Sassone-Corsi highlighted
that, in the future, the understanding of the intimate
links between cellular metabolism and the circadian
clock machinery will provide not only critical insights
into system physiology and endocrinology but also
novel avenues for pharmacological intervention to-
wards metabolic disorders and cancer.
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Cancer metabolism and ion/proton dynamics
To sustain a high glycolytic rate, glycolytic cancer cells
rely not only on changes in the nature and expression
level of glycolytic enzymes and transporters, but also on
pumps and other proteins that control intracellular pH, to
which glycolysis is exquisitely sensitive. Activation of
transcription factors, notably hypoxia-inducible factor-1
(HIF-1), equips glycolytic cancer cells with various systems
for proton export. Together with membrane-bound
vacuolar-type ATPase (V-ATPase), carbonic anhydrases
(CAs; that catalyze the reversible conversion of proton and
bicarbonate to CO2 and water, and work in tandem with
bicarbonate transporters), sodium-proton exchangers
(NHEs), and proton-lactate symporters of the monocarbox-
ylate transporter family (MCTs) contribute to net acid export
(Fig. 2). Their activities often result in a slightly alkaline
intracellular pH that promotes glycolysis and creates an
acidic extracellular pH (pHe) that facilitates tumor cell
invasion and metastasis. While the interplay between these
different systems is still largely uncharacterized, different
therapeutic and diagnostic/imaging agents are currently be-
ing developed exploiting proton transport systems in cancer.
In a session dedicated to proton dynamics in cancer,
Christian Stock (Hannover Medical School, Germany)
focused on NHE1. NHE1 promotes cancer cell mobility and
can be activated when peptidic hormone angiotensin II
(Ang II) binds to its AT1 receptor expressed by cancer cells,
which is followed by calcium release and calmodulin activa-
tion. Yet, in MV3 melanoma cells overexpressing NHE1,
Ang II had a dual effect. It activated NHE1, which should
promote cell motility, but it also simultaneously increased
cytoskeleton density, cortical stiffness and cell adhesion,
resulting in a net decrease in cellular motility. Thus, neither
Ang II nor AT1 inhibitors such as Losartan influenced
melanoma cell aggressiveness, notably suggesting that AT1
receptor inhibitors can be safely used in melanoma patients.
Claudiu Supuran (University of Florence, Italy) then focused
on CA IX, a membrane-bound CA isoform catalyzing the
extracellular conversion of CO2 and water into bicarbonate
and protons. Based on the X-ray resolution of the crystal
structure of the enzyme in adduct with sulfonamide inhibi-
tors, several classes of promising small molecule CA inhibi-
tors have been identified and developed, including inhibitors
that are selective for membrane-bound CAs. Among these
drugs that reduce pHe, novel ureido-substituted benzene
sulfonamides and coumarins/sulfocoumarins were shown to
selectively and potently inhibit CA IX activity in vitro and to
repress breast cancer growth and metastasis in in vivo
models of mice carrying orthotopic human breast cancers.
Thus, targeting CA IX pharmacologically is of high
therapeutic interest for cancer patients, especially in
combination with conventional paclitaxel chemotherapy.
Fig. 1 Graphical abstract. The graph represents the major topics that were updated and discussed at the 2nd annual meeting of the International
Society of Cancer Metabolism entitled “Metabolism and microenvironment in cancer plasticity” that took place in Venice, Italy, on September
16–19, 2015
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Accordingly, a phase I trial has been initiated in October
2014 with a first ureidosulfonamide derivative (SLC-0111)
targeted against CA IX. Several short talks further
reinforced the therapeutic rationale of targeting proton
pumps and transporters to inhibit the progression and
aggressiveness of different types of cancer.
Microenvironmental and metabolic control of
tumor survival and aggressiveness
Tumor cells have “learned” to cope with a precarious
microenvironment by various metabolic adaptations, like
autophagy, which is associated with disease progression
and drug resistance, and may well be a hallmark of
identifying surviving cells in an acidic environment.
Robert Gillies (Moffitt Cancer Center and Research
Institute, Tampa, FL, USA) showed elevated levels of
autophagy-related proteins and intracellular vesicles
typical of autophagy in tumor cells that had been
adapted to grow at pHe 6.6. Proteomics of acid-adapted
cells revealed increased expression of LAMP2, a glyco-
sylated protein of lysosomal membranes, and it was
further shown that LAMP2 translocated to the cell
surface in acid-adapted cells. This protein, whose ex-
pression increased with increasing tumor grade, plays a
crucial role in tumor survival. A promising drug to
undermine this survival mechanism has been chloro-
quine, albeit with the drawback that it is inactive at
acidic pH. Here, Angelo De Milito (Karolinska Institutet,
Stockholm, Sweden) reported that salinomycin blocks
autophagy in acidosis and is well accumulated by the
tumor cells. Moreover, cancer stem cells are more sensi-
tive to this compound than the tumor cells. All this
makes salinomycin an attractive candidate for future
clinical applications.
Fig. 2 Link between proton dynamics and cancer metabolism. The cartoon represents glycolytic and oxidative cancer cells that can coexist in
various types of cancers. Glycolytic cancer cells are well equipped for proton export. Passive transporters comprise monocarboxylate transporters
(MCTs) among which MCT4 is well adapted for proton export, the sodium-proton exchanger NHE1, and the carbonic anhydrase IX (CA-IX)-so-
dium-bicarbonate exchanger (NBC) system that controls a cycle using bicarbonate to export protons. For intracellular ionic homeostasis, the NaK-
ATPase exports sodium against potassium. In addition, proton pump V-ATPase can export protons when expressed at the plasma membrane. Of note,
MCTs convey not only protons but also lactate, which is at the base of a metabolic relationship between glycolytic cancer cells that export lactate via
MCT4 and oxidative cancer cells that import lactate primarily via MCT1 and use lactate to fuel OXPHOS and for intracellular signaling. Proton export
and lactate exchange promote tumor growth, progression and dissemination, which constitutes the rationale for the preclinical and clinical evaluation
of the various inhibitors represented in red. Figure adapted from [2]
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Still much is to be learned on how nutrient levels change
tumor metabolism and survival. The survival of MCF-7
cells is enhanced when limiting glucose and glutamine are
in balance, e.g., 2.5 and 0.1 mM, respectively. In low
glucose, tumor cells can switch to metabolizing lactate,
concomitantly with an increase in cytosolic NADH levels
and surface membrane NADH oxidase activity. Tumor cells
can also resort to autophagy and enhance glutamine
metabolism to ensure cell survival. As “omic” technology
showed, this goes along with an activation of the protein
kinase A pathway. In contrast, glucose levels may also be
modulated by unexpected means related to cancer progres-
sion: in a mouse hepatic tumor model, the expression of
AAA+ ATPase Ruvbl1 (an actin-binding and chromatin-
remodeling protein) is related to poor prognosis; its reduc-
tion, however, was found to correlate with a high serum
glucose level, insulin resistance, and reduced mTOR signal-
ing, and eventually lead to larger tumors.
Metabolic reprogramming means changes in signaling
and expression networks leading to survival and drug
resistance; and the multitude of mechanisms involved
was illustrated by very different studies. Breast cancer
cells adapted to estrogen depletion acquire resistance to dif-
ferent metabolic inhibitors by being able to switch between
glycolysis and oxidative phosphorylation (OXPHOS). On
the other hand, AMP-activated protein kinase regulates the
expression of estrogen-related receptors, which negatively
regulate the expression of folate cycle genes, thereby at-
tenuating purine synthesis. Similarly to cells from solid
tumors, also leukemia cells exploit glutamine as an energy
source: they can cope with glutamine deprivation by acti-
vating the serine pathway. Energy shortage and hypoxia dif-
ferentially regulate the expression of the prognostic marker
BCR/Abl. A possible crosstalk of adenosine and hypoxia
was shown in leukemia by upregulation of the A2A adeno-
sine receptor, which plays a role in the immune system.
Interestingly, the expression of hemoglobin β was found to
correlate with an increase in the expression of the tran-
scription factor HIF-1α and the degree of malignancy in
breast cancer samples. A new aspect in drug resistance is
the role of exosomes: such nanovesicles derived from che-
moresistant osteosarcoma cells are taken up by sensitive
cells and endow these cells with drug resistance. It will be
interesting to see how such exosomes might modulate
tumor metabolism.
Microenvironmental and metabolic control of
epigenetic and stemness
Data presented by Tokuhiro Chano (Shiga University of
Medical Science, Otsu, Shiga, Japan) demonstrated that
acidification of the tumor microenvironment by glyco-
lytic osteosarcoma cells induces a negative feedback on
glycolytic metabolism, associated with an increase in
amino acid catabolism and urea cycle enhancement. It is
noteworthy that metabolites associated with epigenetic
chromatin modification, like UDP-glucose and N8-acetyl
spermidine, were decreased in osteosarcoma cells com-
pared to normal fibroblasts. Chano showed that osteosar-
coma cells under an acidic microenvironment acquire a
higher epigenetic stability with respect to normal cells and
are more sensitive to a histone deacetylase inhibitor.
An interesting hypothesis was presented by Olivier
Feron (Université catholique de Louvain, Brussels,
Belgium), who discussed the relationship between glyco-
lytic metabolism and the epigenetic status of cancer cells
in the context of drug resistance. Therapies targeting the
use of specific carbon sources (like glucose) might elicit
a cellular response leading to resistance. The activity of a
classical antiglycolytic agent, the pyruvate mimetic 3-
bromopyruvate (3-BP), was discussed. This drug enters
the cells via MCT1. The expression of MCT1 is lost in
cancer cells that develop resistance to treatment with 3-
BP. Investigation of the potential mechanism that medi-
ated drug resistance indicated that the MCT1-encoding
gene SLC16A1 is hypermethylated. This suggests that
epigenetic changes associated with the altered metabol-
ism of tumor cells may affect or promote a stem-like
phenotype.
In line with this concept, it was reported that chronic
acidosis strongly affects tumor cell metabolism by in-
creasing glutamine and fatty acid use while decreasing
glycolysis. This metabolic shift is associated with a global
change in the acetylation of mitochondrial proteins that
might be critical to support the adaptation of tumor cell
metabolism under acidosis.
The relationship between cancer metabolism and
stemness was further addressed by the speakers of the
short talks. A model of glioblastoma cancer stem-like
cells (CSCs) derived from tumor biopsies was used to re-
produce the metabolically stressed conditions in which
these cells are thought to reside in vivo. Thus, glioblast-
oma CSCs were grown in conditions leading to acidosis,
hypoxia, and cellular quiescence. Screening of the Prest-
wick chemical library identified bisacodyl as a potent
compound able to selectively kill glioblastoma GSC in a
pH-dependent manner. In another study, the metabolic
activity of tumor cells derived from the biopsies of glio-
blastoma allowed the identification of four different sub-
types of tumors with a high degree of therapy resistance
that could be reversed upon differentiation. Interestingly,
the mesenchymal subtype showed increased glutamine
oxidation and was sensitive to inhibition of mitochon-
drial glutamine metabolism. In melanoma, targeting the
tyrosine kinase c-Met produced an increase in the num-
ber of CSCs in the tumor cell populations that showed a
higher glycolytic rate and a higher sensitivity to the gly-
colitic inhibitor dichloroacetate. Finally, for pancreatic
ductal adenocarcinoma, the ability of cancer-associated
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fibroblasts to modulate the epithelial-to-mesechymal
transition (EMT) and the behavior and the invasive abil-
ity of CSCs in respect to parental cells was discussed.
Cancer metabolism and stroma
Stefano Indraccolo (University of Padova, Padova, Italy)
highlighted how highly glycolytic tumors are resistant to an
antiangiogenic treatment with an anti-VEGF and that, after
the treatment, poorly glycolytic tumors become highly
glycolytic, with a decreased expression of the mitochondrial
complex protein NDUFS1 and increased pSTAT3 levels
that concurred later on to an increased tumor resistance
and aggressiveness. However, as shown by Michael Lisanti
(Manchester University, Manchester, UK), oxidative phos-
phorylation can be associated with tumor recurrence, me-
tastasis, and poor clinical outcome in patients and with a
high fraction of CSCs in the tumor cell population. Accord-
ing to the Reverse Warburg Effect hypothesis, Lisanti
reported that the stromal tumor microenvironment pro-
vides catabolites (e.g., lactate and ketone bodies) for fueling
oxidative mitochondrial metabolism in anabolic cancer
cells. Therefore, inhibitors of mitochondrial protein transla-
tion, like the antibiotic doxycycline, may hold promise for
the eradication of CSCs across multiple tumor types. These
novel discoveries are crucial for the development of future
therapies and underline how therapy-driven evolutionary
dynamics of tumor metabolism should be systematically
considered to eradicate cancer. Similarly, Paola Chiarugi
(University of Florence, Florence, Italy) elucidated how
cancer-associated fibroblasts (CAFs) induce EMT, meta-
bolic reprogramming towards OXPHOS and activation of
the lactate shuttle in cancer cells, altogether promoting
tumor growth and metastatic dissemination. EMT-driven
oxidative signaling leads to PKM2 oxidation and Src-
mediated phosphorylation, nuclear migration, association
with HIF-1, down-regulation of miR205 of PKM2, and acti-
vation of OXPHOS through SIRT1-PGC1α regulation. Fi-
nally, Chiarugi showed a clear reprogramming towards
OXPHOS in relapsing colon cancers resistant to 5-
fluorouracil (5-FU) therapy, with an inversion of the
PKM1/PKM2 ratio, an activation of the pentose phosphate
pathway and a respiratory phenotype addicted to the
SIRT1-PGC1α pathway. Novel findings were also presented
in the short talks, including the ability of breast carcinoma
and melanoma cells with dysfunctional mitochondria to re-
store their mitochondrial function and tumorigenic cap-
acity by acquiring mitochondria from host cells, the ability
of breast carcinoma to promote osteolysis associated with
bone metastases by fueling oxidative bone-resorbing osteo-
clasts with lactate, and the observation that osteosarcoma
cells induce an acidic stress to the mesenchymal stroma,
which, in turn, secrete pro-inflammatory cytokines that
promote cancer migration and stemness.
Targeting and monitoring cancer metabolism and
the altered microenvironment
Different strategies based on the altered metabolism and
microenvironment of cancer were presented. One of the
most technologically advanced strategies was summa-
rized by Paolo Caliceti (University of Padova, Padova,
Italy), the use of nanocarriers (NC). Nanotechnology of-
fers a variety of opportunities to ameliorate the selectiv-
ity and therapeutic activity of anticancer drugs, also
based on the peculiar biological aspects of tumors and
of the tumor microenvironment. NC are last-generation
delivery systems that are capable of sequentially over-
coming multiple biobarriers following a certain time/site
determined “logic” of events and that provide longer
drug circulation times, higher tolerability, and site-
specific delivery. An example of these are bioconjugates
that are obtained by pullulan derivatization with doxo-
rubicin via hydrazone bond and that possess suitable
physicochemical properties for passive tumor targeting
via enhanced permeability and retention (EPR) effects,
prolonged body exposure, and pH-dependent drug re-
lease. Another type of NC is based on stimuli-sensitive
polyacrylates that can be used to produce assemblies,
namely micelles, pH-sensitive liposomes, polymersomes,
as well as nanoparticles for selective drug release or to
trigger the surface properties of inert surfaces. A com-
pletely different carrier for anticancer therapy was sug-
gested by Massimo Dominici (University of Modena and
Reggio Emilia, Italy) who used engineered cells, mesen-
chymal stromal cells (MSCs), that are attracted by the
tumor microenvironment, as a “smart” vehicle of mole-
cules that are cytotoxic only for tumor cells. In the study
presented by Dominici, the anti-tumor molecule carried
by MSCs was the tumor necrosis factor‐related apoptosis‐
inducing ligand (TRAIL). Dominici showed the first
promising results in preclinical models that were obtained
in sarcomas and pancreatic cancers that are both malig-
nancies still characterized by a poor prognosis. Several
short talks further identified novel possible targets or bio-
markers, like lactate dehydrogenase B, Stat3 or glutamine
uptake, glutamate dehydrogenase 1 (GDH1), mTORC1/
mTORC2 and glycolytic pathways to be combined, nico-
tinamide phosphoribosyltransferase (NAMPT), the mito-
chondrial molecular chaperone TRAP1, and Verteporfin
as a selective anticancer drug in an acidic microenviron-
ment. Statins were suggested as possible biomarkers to
identify those patients to be treated with anti-metabolic
therapies, and choline metabolism as an early predictor of
therapeutic efficiency.
The specific cancer metabolic activities were then
exploited for monitoring by Elizabeth Maher (University
of Texas Southwestern Medical Center, TX, USA) who
presented, as an example, recent findings on the funda-
mental role of acetate in one - carbon metabolism and
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biosynthesis in glioblastoma, and described how it can
be used in cancer imaging. The study focused on under-
standing the key reprogramming events driving early
transformation in gliomas, and revealed a “bioenergetic
substrate gap” whereby the acetyl-CoA pool is not exclu-
sively derived from glucose. [13C]-acetate is oxidized to
acetyl-CoA by the enzyme ACSS2, and thereby provides
an additional source of acetyl-CoA and its incorporation
into glutamate. Expression of ACSS2 correlated strongly
with survival, and positron emission tomography uptake
of [11C]-acetate was demonstrated as a strong imaging
biomarker, prognostic of malignant transformation in
glioblastoma. Of particular interest, the co-oxidation of
acetate and glucose appears to be a feature not only of
gliomas before they transform into glioblastomas, but
also of metastatic tissue from cells of different primary
origin, thus suggesting that acetate metabolism is an
adaptive mechanism in malignancies of the brain.
Finally, another novel and interesting method for cancer
monitoring was proposed in a short talk on the use of
EPR-based spectroscopy and imaging to test specific pat-
terns of chemical tumor microenvironment parameters
associated with cancer metabolism, namely high redu-
cing capacity, hypoxia (pO2), and pHe.
Other sessions
In addition to the main topics mentioned above, the role
of diabetes and diet in cancer metabolism and the identifi-
cation of new preclinical models were actively discussed.
Laura Sciacca (University of Catania, Catania, Italy)
argued how diabetes and metabolic disturbances, such as
type 2 diabetes mellitus (T2DM) and obesity, are associ-
ated with an increased cancer risk. In this context, hyper-
glycemia, hyperinsulinemia, and the associated increase in
the level of other hormones like glucagon, leptin, incre-
tins, and the activation of the insulin receptor (IR) and the
IGF‐1 receptor (IGF‐1R) have a major role. Hyperinsuline-
mia, in addition to having a metabolic action, activates IR
and IGF-1R signaling that are also involved in cancer pro-
gression. Hyperglycemia provides energy promoting can-
cer growth and neoangiogenesis, and affects IGF‐1R
signaling. Laure Bindels (Université catholique de Louvain,
Belgium) showed that diet can strongly impact cancer
metabolism, especially in cachectic subjects, by altering
the composition of the gut microbiota that, in turn, is a
crucial regulator of host immunity and metabolism. By
studying several mouse models of cancer cachexia, the
group of Bindels found that systemic inflammation due to
cancer development alters the gut permeability, antimicro-
bial defense and Paneth cell function, leading to dysbiosis.
This gives rise to a vicious cycle where cancer‐induced
alterations of intestinal homeostasis foster the growth of
pathobionts, which further increase systemic inflamma-
tion and cachexia through the translocation of bacterial
compounds. Finally, Bindels found that the use of probio-
tics and prebiotics confers benefits to the host in terms of
lifespan, cancer proliferation, and cachexia. Regarding the
use of new preclinical models to study cancer metabolism
and microenvironment that were proposed during the
conference, one must mention the use of large-scale in
silico metabolic models or computational and mathemat-
ical approaches to predict the interaction between human
cells in defined microenvironments, or to find suitable
therapy protocols, like immunotherapy in cancer, and
the use of engineered organotypic tumor microenvir-
onment models that include both fibroblasts and can-
cer cells on a collagen matrix to recapitulate the
microenvironmental architecture.
Conclusion
This conference illustrated the high level of complexity
of the interplay between cancer metabolism and micro-
environment and the challenges ahead in our attempt to
ultimately identify anticancer agents that can be trans-
lated to the clinics. A good example of cancer metabol-
ism research that extends from the laboratory to the
clinics was summarized by Michael Pollak (McGill Uni-
versity, Montreal, Canada) in the closing lecture that de-
scribed the use of the antidiabetic biguanide drug
metformin in cancer. Pollak mentioned that although
hundreds of papers have been published on the use of
metformin in cancer, the precise mechanism of antineo-
plastic effect is not well defined, and may involve several
mechanisms, like host hormonal milieu and energetic
stress, or energetic crisis and cytotoxicity in cancers that
are intolerant to energetic stress, or an anti‐inflamma-
tory action related to inhibition of NF‐kB. To date, initial
clinical studies have confirmed that metformin perturbs
many biomarkers, including levels of a variety of hor-
mones potentially relevant to cancer, and also influences
biomarkers measured in tumor tissue, such as Ki67.
From pharmacokinetic studies, we now know that met-
formin may be particularly suitable for cancer risk
reduction in the liver, GI tract, and GU tract, since it
predominantly accumulates in and targets these spe-
cific tissues. However, Pollak underlined that it re-
mains to be established if the magnitude of these
changes is sufficient to lead to any clinical benefit,
also because the first randomized placebo‐controlled
clinical trial of metformin with a survival endpoint in
advanced pancreatic cancer showed no effect. How-
ever, many other trials are ongoing, and this result
should not be generalized to other cancer types or to
applications in risk reduction.
The ISCaM2015 conference provided the audience with
a broad sampling of up-to-date knowledge about the plas-
ticity of cancer cells to survive and progress in different
microenvironments through metabolic adaptations and
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how this feature can be advantageously used for tumor -
targeting and monitoring. Next year’s ISCaM meeting will
be held in Brussels between the 26th and 29th of October,
and its theme will be 'metabolic networks in cancers'.
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